| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:YBX1_AXL |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: YBX1_AXL | KinaseFusionDB ID: KFG7190 | FusionGDB2.0 ID: KFG7190 | Hgene | Tgene | Gene symbol | YBX1 | AXL | Gene ID | 4904 | 558 | |
| Gene name | Y-box binding protein 1 | AXL receptor tyrosine kinase | ||||||||||
| Synonyms | BP-8|CBF-A|CSDA2|CSDB|DBPB|EFI-A|MDR-NF1|NSEP-1|NSEP1|YB-1|YB1 | ARK|AXL3|JTK11|Tyro7|UFO | ||||||||||
| Cytomap | 1p34.2 | 19q13.2 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | Y-box-binding protein 1CCAAT-binding transcription factor I subunit ADNA-binding protein BY-box transcription factorenhancer factor I subunit Amajor histocompatibility complex, class II, Y box-binding protein Inuclease-sensitive element-binding prot | tyrosine-protein kinase receptor UFOAXL oncogeneAXL transforming sequence/gene | ||||||||||
| Modification date | 20240411 | 20240416 | ||||||||||
| UniProtAcc | P67809 | P30530 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000321358, ENST00000467957, | ENST00000301178, ENST00000359092, ENST00000594880, ENST00000593513, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: YBX1 [Title/Abstract] AND AXL [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ||||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | YBX1 | GO:0006355 | regulation of DNA-templated transcription | 18809583 |
| Hgene | YBX1 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 18809583 |
| Hgene | YBX1 | GO:0048255 | mRNA stabilization | 31358969 |
| Hgene | YBX1 | GO:0070934 | CRD-mediated mRNA stabilization | 19029303 |
| Hgene | YBX1 | GO:1900152 | negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 19029303 |
| Hgene | YBX1 | GO:1990428 | miRNA transport | 27559612 |
| Hgene | YBX1 | GO:2000767 | positive regulation of cytoplasmic translation | 19029303 |
| Tgene | AXL | GO:0001961 | positive regulation of cytokine-mediated signaling pathway | 18840707 |
| Tgene | AXL | GO:0006909 | phagocytosis | 21501828 |
| Tgene | AXL | GO:0032689 | negative regulation of type II interferon production | 18840707 |
| Tgene | AXL | GO:0032825 | positive regulation of natural killer cell differentiation | 18840707 |
| Tgene | AXL | GO:0035457 | cellular response to interferon-alpha | 19657094 |
| Tgene | AXL | GO:0071222 | cellular response to lipopolysaccharide | 19657094 |
| Tgene | AXL | GO:2000669 | negative regulation of dendritic cell apoptotic process | 19657094 |
| Kinase Fusion gene breakpoints across YBX1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across AXL (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| CCLE | SW 1088 | YBX1 | chr1 | 43161936 | AXL | chr19 | 41766651 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:/:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| YBX1 | AXL |
| FUNCTION: DNA- and RNA-binding protein involved in various processes, such as translational repression, RNA stabilization, mRNA splicing, DNA repair and transcription regulation (PubMed:8188694, PubMed:10817758, PubMed:11698476, PubMed:14718551, PubMed:18809583, PubMed:31358969). Predominantly acts as a RNA-binding protein: binds preferentially to the 5'-[CU]CUGCG-3' RNA motif and specifically recognizes mRNA transcripts modified by C5-methylcytosine (m5C) (PubMed:19561594, PubMed:31358969). Promotes mRNA stabilization: acts by binding to m5C-containing mRNAs and recruiting the mRNA stability maintainer ELAVL1, thereby preventing mRNA decay (PubMed:10817758, PubMed:11698476, PubMed:31358969). Component of the CRD-mediated complex that promotes MYC mRNA stability (PubMed:19029303). Contributes to the regulation of translation by modulating the interaction between the mRNA and eukaryotic initiation factors (By similarity). Plays a key role in RNA composition of extracellular exosomes by defining the sorting of small non-coding RNAs, such as tRNAs, Y RNAs, Vault RNAs and miRNAs (PubMed:27559612, PubMed:29073095). Probably sorts RNAs in exosomes by recognizing and binding C5-methylcytosine (m5C)-containing RNAs (PubMed:28341602, PubMed:29073095). Acts as a key effector of epidermal progenitors by preventing epidermal progenitor senescence: acts by regulating the translation of a senescence-associated subset of cytokine mRNAs, possibly by binding to m5C-containing mRNAs (PubMed:29712925). Also involved in pre-mRNA alternative splicing regulation: binds to splice sites in pre-mRNA and regulates splice site selection (PubMed:12604611). Binds to TSC22D1 transcripts, thereby inhibiting their translation and negatively regulating TGF-beta-mediated transcription of COL1A2 (By similarity). Also able to bind DNA: regulates transcription of the multidrug resistance gene MDR1 is enhanced in presence of the APEX1 acetylated form at 'Lys-6' and 'Lys-7' (PubMed:18809583). Binds to promoters that contain a Y-box (5'-CTGATTGGCCAA-3'), such as MDR1 and HLA class II genes (PubMed:8188694, PubMed:18809583). Promotes separation of DNA strands that contain mismatches or are modified by cisplatin (PubMed:14718551). Has endonucleolytic activity and can introduce nicks or breaks into double-stranded DNA, suggesting a role in DNA repair (PubMed:14718551). The secreted form acts as an extracellular mitogen and stimulates cell migration and proliferation (PubMed:19483673). {ECO:0000250|UniProtKB:P62960, ECO:0000250|UniProtKB:Q28618, ECO:0000269|PubMed:10817758, ECO:0000269|PubMed:11698476, ECO:0000269|PubMed:12604611, ECO:0000269|PubMed:14718551, ECO:0000269|PubMed:18809583, ECO:0000269|PubMed:19029303, ECO:0000269|PubMed:19483673, ECO:0000269|PubMed:19561594, ECO:0000269|PubMed:27559612, ECO:0000269|PubMed:28341602, ECO:0000269|PubMed:29073095, ECO:0000269|PubMed:29712925, ECO:0000269|PubMed:31358969, ECO:0000269|PubMed:8188694}. | FUNCTION: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, AXL binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958, ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074, ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062, ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}.; FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and lymphocytic choriomeningitis virus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:21501828, ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:25277499}.; FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. {ECO:0000269|PubMed:22673088}.; FUNCTION: (Microbial infection) Promotes Zika virus entry in glial cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:29379210, PubMed:31311882). Additionally, Zika virus potentiates AXL kinase activity to antagonize type I interferon signaling and thereby promotes infection (PubMed:28076778). Interferon signaling inhibition occurs via an SOCS1-dependent mechanism (PubMed:29379210). {ECO:0000269|PubMed:28076778, ECO:0000269|PubMed:29379210, ECO:0000269|PubMed:31311882}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of YBX1_AXL |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| AXL | P30530 | human | MLKL | Q8NB16 | Y376 | DRVkstAyLSPQELE | PK_Tyr_Ser-Thr |
| AXL | P30530 | human | ELMO2 | Q96JJ3 | Y713 | IPKEPssyDFVyHyG | |
| AXL | P30530 | human | AKT1 | P31749 | S473 | RPHFPQFsysAsGtA | Pkinase_C |
| AXL | P30530 | human | STAT5A | P42229 | Y694 | LAkAVDGyVkPQIkQ | |
| AXL | P30530 | human | ELMO1 | Q92556 | Y724 | PsNyDFVyDCN____ | |
| AXL | P30530 | human | STAT3 | P40763 | Y705 | DPGsAAPyLktKFIC | |
| AXL | P30530 | human | LCK | P06239 | Y394 | RLIEDNEytAREGAk | PK_Tyr_Ser-Thr |
| AXL | P30530 | human | FYN | P06241 | Y420 | RLIEDNEytARQGAk | PK_Tyr_Ser-Thr |
| AXL | P30530 | human | ELMO1 | Q92556 | Y720 | IPKEPsNyDFVyDCN | |
| AXL | P30530 | human | LYN | P07948 | Y397 | RVIEDNEytAREGAk | PK_Tyr_Ser-Thr |
| AXL | P30530 | human | HCK | P08631 | Y411 | RVIEDNEytAREGAk | PK_Tyr_Ser-Thr |
| AXL | P30530 | human | STAT5B | P51692 | Y699 | tAkAVDGyVkPQIkQ | |
| AXL | P30530 | human | SRC | P12931 | Y419 | RLIEDNEytARQGAk | PK_Tyr_Ser-Thr |
| AXL | P30530 | human | YES1 | P07947 | Y426 | RLIEDNEytARQGAk | PK_Tyr_Ser-Thr |
| AXL | P30530 | human | AKT1 | P31749 | T308 | kDGAtMKtFCGtPEy | Pkinase |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| AXL | ID | Description | 0.00e+00 |
| AXL | GO:0038094 | Fc-gamma receptor signaling pathway | 3.80e-11 |
| AXL | GO:0031295 | T cell costimulation | 1.81e-10 |
| AXL | GO:0031294 | lymphocyte costimulation | 1.81e-10 |
| AXL | GO:0038093 | Fc receptor signaling pathway | 2.77e-10 |
| AXL | GO:0002433 | immune response-regulating cell surface receptor signaling pathway involved in phagocytosis | 8.89e-10 |
| AXL | GO:0038096 | Fc-gamma receptor signaling pathway involved in phagocytosis | 8.89e-10 |
| AXL | GO:0002431 | Fc receptor mediated stimulatory signaling pathway | 2.33e-09 |
| AXL | GO:0002862 | negative regulation of inflammatory response to antigenic stimulus | 2.40e-09 |
| AXL | GO:0060397 | growth hormone receptor signaling pathway via JAK-STAT | 3.99e-09 |
| AXL | GO:0060416 | response to growth hormone | 4.05e-09 |
| AXL | GO:0050900 | leukocyte migration | 4.74e-09 |
| AXL | GO:0006909 | phagocytosis | 7.66e-09 |
| AXL | GO:0050870 | positive regulation of T cell activation | 9.84e-09 |
| AXL | GO:0002861 | regulation of inflammatory response to antigenic stimulus | 9.84e-09 |
| AXL | GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 1.74e-08 |
| AXL | GO:0031348 | negative regulation of defense response | 4.62e-08 |
| AXL | GO:0022409 | positive regulation of cell-cell adhesion | 4.62e-08 |
| AXL | GO:0051251 | positive regulation of lymphocyte activation | 5.17e-08 |
| AXL | GO:0002437 | inflammatory response to antigenic stimulus | 1.01e-07 |
| AXL | GO:0060396 | growth hormone receptor signaling pathway | 1.03e-07 |
| AXL | GO:1901653 | cellular response to peptide | 1.03e-07 |
| AXL | GO:0002696 | positive regulation of leukocyte activation | 1.03e-07 |
| AXL | GO:0050863 | regulation of T cell activation | 1.03e-07 |
| AXL | GO:0071378 | cellular response to growth hormone stimulus | 1.03e-07 |
| AXL | GO:1903037 | regulation of leukocyte cell-cell adhesion | 1.03e-07 |
| AXL | GO:0050728 | negative regulation of inflammatory response | 1.10e-07 |
| AXL | GO:0050777 | negative regulation of immune response | 1.15e-07 |
| AXL | GO:0050867 | positive regulation of cell activation | 1.18e-07 |
| AXL | GO:0007159 | leukocyte cell-cell adhesion | 1.69e-07 |
| AXL | GO:0050727 | regulation of inflammatory response | 1.80e-07 |
| AXL | GO:0032102 | negative regulation of response to external stimulus | 4.04e-07 |
| AXL | GO:0045785 | positive regulation of cell adhesion | 4.04e-07 |
| AXL | GO:0022407 | regulation of cell-cell adhesion | 4.57e-07 |
| AXL | GO:0018108 | peptidyl-tyrosine phosphorylation | 5.43e-07 |
| AXL | GO:0018212 | peptidyl-tyrosine modification | 5.51e-07 |
| AXL | GO:0052548 | regulation of endopeptidase activity | 6.61e-07 |
| AXL | GO:0071375 | cellular response to peptide hormone stimulus | 9.97e-07 |
| AXL | GO:0052547 | regulation of peptidase activity | 1.01e-06 |
| AXL | GO:0048013 | ephrin receptor signaling pathway | 1.07e-06 |
| AXL | GO:0002429 | immune response-activating cell surface receptor signaling pathway | 1.07e-06 |
| AXL | GO:0070669 | response to interleukin-2 | 1.30e-06 |
| AXL | GO:0070672 | response to interleukin-15 | 1.65e-06 |
| AXL | GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 1.65e-06 |
| AXL | GO:0045862 | positive regulation of proteolysis | 1.72e-06 |
| AXL | GO:0007259 | receptor signaling pathway via JAK-STAT | 2.14e-06 |
| AXL | GO:0097696 | receptor signaling pathway via STAT | 3.09e-06 |
| AXL | GO:0046777 | protein autophosphorylation | 4.01e-06 |
| AXL | GO:0045088 | regulation of innate immune response | 4.98e-06 |
| AXL | GO:0043434 | response to peptide hormone | 5.23e-06 |
Top |
Related Drugs to YBX1_AXL |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning YBX1-AXL and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to YBX1_AXL |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |